Historical Valuation
RenovoRx Inc (RNXT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 12.74 is considered Undervalued compared with the five-year average of -3.00. The fair price of RenovoRx Inc (RNXT) is between 1.34 to 2.98 according to relative valuation methord. Compared to the current price of 1.12 USD , RenovoRx Inc is Undervalued By 16.4%.
Relative Value
Fair Zone
1.34-2.98
Current Price：1.12
16.4%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
RenovoRx Inc (RNXT) has a current Price-to-Book (P/B) ratio of 3.79. Compared to its 3-year average P/B ratio of 149.55 , the current P/B ratio is approximately -97.47% higher. Relative to its 5-year average P/B ratio of 102.61, the current P/B ratio is about -96.31% higher. RenovoRx Inc (RNXT) has a Forward Free Cash Flow (FCF) yield of approximately -33.97%. Compared to its 3-year average FCF yield of -41.05%, the current FCF yield is approximately -17.25% lower. Relative to its 5-year average FCF yield of -37.88% , the current FCF yield is about -10.33% lower.
P/B
Median3y
149.55
Median5y
102.61
FCF Yield
Median3y
-41.05
Median5y
-37.88
Competitors Valuation Multiple
AI Analysis for RNXT
The average P/S ratio for RNXT competitors is 41.96, providing a benchmark for relative valuation. RenovoRx Inc Corp (RNXT.O) exhibits a P/S ratio of 12.74, which is -69.63% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for RNXT
1Y
3Y
5Y
Market capitalization of RNXT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of RNXT in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is RNXT currently overvalued or undervalued?
RenovoRx Inc (RNXT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 12.74 is considered Undervalued compared with the five-year average of -3.00. The fair price of RenovoRx Inc (RNXT) is between 1.34 to 2.98 according to relative valuation methord. Compared to the current price of 1.12 USD , RenovoRx Inc is Undervalued By 16.40% .
What is RenovoRx Inc (RNXT) fair value?
RNXT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of RenovoRx Inc (RNXT) is between 1.34 to 2.98 according to relative valuation methord.
How does RNXT's valuation metrics compare to the industry average?
The average P/S ratio for RNXT's competitors is 41.96, providing a benchmark for relative valuation. RenovoRx Inc Corp (RNXT) exhibits a P/S ratio of 12.74, which is -69.63% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for RenovoRx Inc (RNXT) as of Jan 10 2026?
As of Jan 10 2026, RenovoRx Inc (RNXT) has a P/B ratio of 3.79. This indicates that the market values RNXT at 3.79 times its book value.
What is the current FCF Yield for RenovoRx Inc (RNXT) as of Jan 10 2026?
As of Jan 10 2026, RenovoRx Inc (RNXT) has a FCF Yield of -33.97%. This means that for every dollar of RenovoRx Inc’s market capitalization, the company generates -33.97 cents in free cash flow.
What is the current Forward P/E ratio for RenovoRx Inc (RNXT) as of Jan 10 2026?
As of Jan 10 2026, RenovoRx Inc (RNXT) has a Forward P/E ratio of -2.18. This means the market is willing to pay $-2.18 for every dollar of RenovoRx Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for RenovoRx Inc (RNXT) as of Jan 10 2026?
As of Jan 10 2026, RenovoRx Inc (RNXT) has a Forward P/S ratio of 12.74. This means the market is valuing RNXT at $12.74 for every dollar of expected revenue over the next 12 months.